Drybench Patent.
TREPROSTINIL, NDA 021272
The patents and exclusivities FDA's Orange Book lists for NDA 021272 as captured on 14 October 2026, each date named by its rule and its rows, and the rows of FDA's Paragraph IV list that give this NDA's number, as captured on 17 October 2026. Listed protection is a range of dates, never one date.
FDA capture · review pending. Each row is shown as captured from FDA's Orange Book files and Paragraph IV list. Dates are FDA's own; spreadsheet day numbers are shown as dates, and a cell that cannot be read as one date is shown as written and left out of the range. Where FDA lists a *PED row without flags, its flags are read from the base row and marked so. A Paragraph IV row is placed here only by the number in its RLD/NDA cell; nothing is joined by name. How this page reads FDA's files has not been independently reviewed by a regulatory-affairs reviewer.
- Orange Book captured
- 14 October 2026
- Paragraph IV list captured
- 17 October 2026
- Last checked
- 30 October 2026
- Data-branch commit
- dadcab56563716abea6c5e31a5e1970080c778ef
Listed protection is a range of the dates FDA lists, not a forecast of market entry, and not legal, regulatory or investment advice.
Dates as listed in FDA's Orange Book capture of 14 October 2026. This page does not say whether a date has passed; compare it with today's date and FDA's current Orange Book. This page shows only what the capture of 14 October 2026 lists. It does not show patents or exclusivities listed before and since removed.
Listed protection
Listed dates run from 5 Sep 2028 to 29 Mar 2029, each by its own rule; no one date stands for this product.
- Earliest listed date
- 5 Sep 2028US 8,653,137, use patentRule R1 · Products 001, 002, 003, 004, 005, 006, 007, 008 · patent.txt lines 510, 515, 520, 525, 530, 535, 540, 545
- Latest listed date
- 29 Mar 2029US 7,999,007, product and use patentRule R1 · Products 001, 002, 003, 004, 005, 006, 007, 008 · patent.txt lines 509, 514, 519, 524, 529, 534, 539, 544
- Latest substance patent
- 15 Dec 2028US 9,593,066, substance patentRule R1 · Products 001, 002, 003, 004, 005, 006, 007, 008 · patent.txt lines 512, 517, 522, 527, 532, 537, 542, 547
- Latest listed patent
- 29 Mar 2029US 7,999,007, product and use patentRule R1 · Products 001, 002, 003, 004, 005, 006, 007, 008 · patent.txt lines 509, 514, 519, 524, 529, 534, 539, 544
- Latest exclusivity
- None listed
24 use-code patents, blocking the coded use only
Products
Each product number FDA lists under NDA 021272, as listed. The sections below name products by these numbers.
Product 001 · REMODULIN
- Dosage form; route
- INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
- Strength
- 1MG/ML
- Approval date as listed
- 21 May 2002
- Type as listed
- RX
- Applicant as listed
- UNITED THERAPEUTICS CORP
Product 002 · REMODULIN
- Dosage form; route
- INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
- Strength
- 2.5MG/ML
- Approval date as listed
- 21 May 2002
- Type as listed
- RX
- Applicant as listed
- UNITED THERAPEUTICS CORP
Product 003 · REMODULIN
- Dosage form; route
- INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
- Strength
- 5MG/ML
- Approval date as listed
- 21 May 2002
- Type as listed
- RX
- Applicant as listed
- UNITED THERAPEUTICS CORP
Product 004 · REMODULIN
- Dosage form; route
- INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
- Strength
- 10MG/ML
- Approval date as listed
- 21 May 2002
- Type as listed
- RX
- Applicant as listed
- UNITED THERAPEUTICS CORP
Product 005 · REMODULIN
- Dosage form; route
- INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
- Strength
- 20MG/ML
- Approval date as listed
- 30 Jul 2021
- Type as listed
- DISCN
- Applicant as listed
- UNITED THERAPEUTICS CORP
Product 006 · REMODULIN
- Dosage form; route
- INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
- Strength
- 0.1MG/ML
- Approval date as listed
- 28 Sep 2023
- Type as listed
- DISCN
- Applicant as listed
- UNITED THERAPEUTICS CORP
Product 007 · REMODULIN
- Dosage form; route
- INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
- Strength
- 0.2MG/ML
- Approval date as listed
- 28 Sep 2023
- Type as listed
- DISCN
- Applicant as listed
- UNITED THERAPEUTICS CORP
Product 008 · REMODULIN
- Dosage form; route
- INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
- Strength
- 0.4MG/ML
- Approval date as listed
- 28 Sep 2023
- Type as listed
- RX
- Applicant as listed
- UNITED THERAPEUTICS CORP
Listed patents
Every patent the FDA lists for this product, as the application holder submitted it, with its flags. The FDA does not verify listings.
5 entries from 40 rows as listed; rows merge only where every cell shown is the same, each with its product numbers.
US 8,653,137, use patent
patent.txt lines 510, 515, 520, 525, 530, 535, 540, 545- Expiry as listed
- 5 Sep 2028
- Rule
- R1
- Flags
- use code U-1437
- Product numbers
- 001, 002, 003, 004, 005, 006, 007, 008
US 8,658,694, use patent
patent.txt lines 511, 516, 521, 526, 531, 536, 541, 546- Expiry as listed
- 5 Sep 2028
- Rule
- R1
- Flags
- use code U-1437
- Product numbers
- 001, 002, 003, 004, 005, 006, 007, 008
US 11,723,887, substance patent
patent.txt lines 508, 513, 518, 523, 528, 533, 538, 543- Expiry as listed
- 15 Dec 2028
- Rule
- R1
- Flags
- substance
- Product numbers
- 001, 002, 003, 004, 005, 006, 007, 008
US 9,593,066, substance patent
patent.txt lines 512, 517, 522, 527, 532, 537, 542, 547- Expiry as listed
- 15 Dec 2028
- Rule
- R1
- Flags
- substance
- Product numbers
- 001, 002, 003, 004, 005, 006, 007, 008
US 7,999,007, product and use patent
patent.txt lines 509, 514, 519, 524, 529, 534, 539, 544- Expiry as listed
- 29 Mar 2029
- Rule
- R1
- Flags
- product · use code U-1437
- Product numbers
- 001, 002, 003, 004, 005, 006, 007, 008
Listed exclusivities
Each exclusivity FDA lists for NDA 021272, with its code, FDA's definition of the code where the store's code list gives one, and its date as listed.
The Orange Book capture of 14 October 2026 lists no exclusivity for NDA 021272.
Paragraph IV list rows giving NDA 021272
The rows of FDA's Paragraph IV certifications list as captured on 17 October 2026 whose RLD/NDA cell gives NDA 021272, each cell as listed.
FDA's Paragraph IV list names no patent number, so it does not say which of the patents on this page an applicant certified against.
The list gives the last qualifying patent's expiry without pediatric exclusivity; in the app's Patents view, the Orange Book lists any *PED period as a separate row with its own date. The two dates describe different things. A blank cell is one FDA left blank in its list. Dates are FDA's own; the last qualifying patent expiry is not recomputed from the Orange Book.
Rows whose RLD/NDA cell we could not read as exactly one NDA number are kept apart on the list page; some may concern this product.
Rows on FDA's Paragraph IV list whose RLD/NDA cell gives NDA 021272
Treprostinil Sodium · Injection · 1 mg/mL, 2.5 mg/mL, and 5 mg/mL, 20 mL vial
RLD/NDA as listed: Remodulin 21272- First PIV submission
- 7 Dec 2012
- ANDAs
- 1
- 180-day status
- Eligible
- Decision posted
- 18 Jun 2019
- First applicant approval
- 30 Nov 2017
- First marketing
- 25 Mar 2019
- Last qualifying patent expiry (as listed by FDA)
- 29 Mar 2029
Treprostinil Sodium · Injection · 10 mg/mL, 20 mL vial
RLD/NDA as listed: Remodulin 21272- First PIV submission
- 2 Dec 2011
- ANDAs
- 1
- 180-day status
- Eligible
- Decision posted
- 18 Jun 2019
- First applicant approval
- 30 Nov 2017
- First marketing
- 25 Mar 2019
- Last qualifying patent expiry (as listed by FDA)
- 29 Mar 2029
Notes from the trace
- R6 tentative approvals: not in the Orange Book data files as captured; the Drugs@FDA join is a later ruling.
Patents vs FDA exclusivityHow to read the Orange Book data filesParagraph IV certificationWhat changed, by week